.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Cipla
Novartis
Julphar
McKinsey
Daiichi Sankyo
Mallinckrodt
UBS
Citi

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,004,973

« Back to Dashboard

Which drugs does patent 6,004,973 protect, and when does it expire?


Patent 6,004,973 protects AFINITOR DISPERZ, AFINITOR, and ZORTRESS, and is included in three NDAs. There have been zero Paragraph IV challenges on Afinitor Disperz, Afinitor, and Zortress.

Protection for AFINITOR DISPERZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,004,973

Title: Pharmaceutical compositions comprising rafamycin coprecipitates
Abstract:Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.
Inventor(s): Guitard; Patrice (Hegenheim, FR), Haeberlin; Barbara (Riehen, CH), Link; Rainer (Staufen, DE), Richter; Friedrich (Grenzach-Wyhlen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:08/981,952
Patent Claim Types:
see list of patent claims
Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-001Aug 29, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-002Aug 29, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-003Aug 29, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
NovartisAFINITOReverolimusTABLET;ORAL022334-003Jul 9, 2010RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisAFINITOReverolimusTABLET;ORAL022334-001Mar 30, 2009RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisAFINITOReverolimusTABLET;ORAL022334-004Mar 30, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisAFINITOReverolimusTABLET;ORAL022334-002Mar 30, 2009RXYesYes► Subscribe► Subscribe► SubscribeY
NovartisZORTRESSeverolimusTABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisZORTRESSeverolimusTABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisZORTRESSeverolimusTABLET;ORAL021560-003Apr 20, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,004,973

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9514397Jul 14, 1995
United Kingdom9515025Jul 21, 1995
PCT Information
PCT FiledJuly 12, 1996PCT Application Number:PCT/EP96/03066
PCT Publication Date:February 06, 1997PCT Publication Number: WO97/03654

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Fish and Richardson
Mallinckrodt
Colorcon
McKesson
US Department of Justice
Johnson and Johnson
Covington
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot